New products lead GSK to beat forecasts with 1st-qtr sales

27 April 2016
gskbig

Increased sales of new products, better profit margins and internal restructuring and integration have been cited as reasons for pharma major GlaxoSmithKline (LSE: GSK) reporting strong first-quarter growth for 2016.

The UK’s biggest pharma company reports that its sales have risen by 8% during the quarter, with £6.2 billion ($9 billion) raised, generating core earnings per share of 19.8 pence.

GSK has declared a dividend of 19 pence for the quarter and continues to expect to pay a full year dividend of 80 pence for 2016 and for 2017.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical